Highlights of the Financial Results declared for the year ended 31st March , 2010

Gross Sales: Q4 FY10 up 35.90% to Rs. 183.78 Crores; FY10 up 30.10% to Rs.559.00 Crores Launch of 5 new products in Cephalosporin antibiotic APIs, oral and sterile range Penetration of new geographies – exports made to 45 countries in fiscal 2010 EBIDTA: Q4 FY10 EBITDA up 19.66% to Rs. 26.35 Crores; FY10 up 41.17% to Rs. 92.33 Crores. EBITDA as a percentage of Net Sales was 17.97% in FY10 as compared to 16.53% in FY09. Launch of  4th and 5th generation Cephalosporin APIs boosted EBITDA margins Sales to new geographies also contributed to better EBIDTA margins Net Profit: Q4 FY10 up 105.71% to Rs. 11.52 Crores; FY10 up 42.84% to Rs. 34.20 Crores. Key Highlights Received Certificate of Suitability (“COS”) from the European Directorate for the Quality of Medicines (and Healthcare), France (“EDQM”) for its DMF filed for Cefuroxime Axetil Amorphous - granting permission to sell the product in the regulated markets of the European Union Executed 8 custom synthesis contracts for global innovator and biotech companies since January 2010 Signed long term sales contracts with Ranbaxy, Lindopharm Germany and Chemworth USA Commercial production at phase I of the Chachrauli facility for manufacturing non-antibiotic products to start in September 2010. Company has a pipeline of 20 non-antibiotic products Expect total capacity expansion of 80% in the next twelve months time Go Back | Home